<DOC>
	<DOC>NCT02100319</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of azilsartan tablets (Azilva Tablets) in patients with hypertension complicated by diabetes mellitus whose blood pressure cannot be sufficiently reduced by monotherapy with angiotensin II receptor blockers (ARBs) other than azilsartan, in routine clinical practice</brief_summary>
	<brief_title>Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "</brief_title>
	<detailed_description>This study was designed to evaluate the efficacy of azilsartan tablets (Azilva Tablets) in patients with hypertension complicated by diabetes mellitus whose blood pressure cannot be sufficiently reduced by monotherapy with ARBs, other than azilsartan, in daily medical practice. Subject enrollment will be started on April 1, 2014. The usual dosage for adults is 20 mg of azilsartan administered orally once daily. The dose can be adjusted according to the patient's age and condition. The maximum daily dose is 40 mg.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Patients with hypertension who meet all the following criteria will be enrolled: 1. Patients who has complications of diabetes mellitus 2. Patients who is on monotherapy with ARBs (other than azilsartan) as antihypertensive treatment (Patients who have continued monotherapy with the same ARB product for at least 8 weeks at the time of Step1* of subject enrollment and will continue such treatment until the first administration of Azilva Tablets) 3. Patients who has a systolic blood pressure of ≥ 130 mmHg and/or diastolic blood pressure of 80 ≥ mmHg at the examination performed at the medical institution 4. Patients who is an outpatient 5. Patient who keeps a regular lifestyle and whose usual waking time is between 4 a.m. and 9:30 a.m. For this surveillance, subject enrollment will be performed in two divided steps: Step1 (at hospital visit before prescription of Azilva Tablets) and Step2 (at the time of prescription of Azilva Tablets). Patients with contraindications to azilsartan</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>